4//SEC Filing
Korbel Gregory Alan 4
Accession 0001104659-21-118363
CIK 0001781983other
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 5:01 PM ET
Size
11.0 KB
Accession
0001104659-21-118363
Insider Transaction Report
Form 4
Korbel Gregory Alan
VP of Business Dev't
Transactions
- Sale
Common Stock
2021-09-20$4.97/sh−27,500$136,675→ 17,167 total - Exercise/Conversion
Common Stock
2021-09-20$0.92/sh+27,500$25,300→ 44,667 total - Exercise/Conversion
Stock Option (right to Buy)
2021-09-20−27,500→ 52,745 totalExercise: $0.92Exp: 2026-09-14→ Common Stock (27,500 underlying) - Sale
Common Stock
2021-09-20$4.98/sh−5,460$27,191→ 17,167 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.76 to $5.48 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $5.54 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]This option was granted on September 14, 2016 and is fully exercisable.
Documents
Issuer
Aprea Therapeutics, Inc.
CIK 0001781983
Entity typeother
Related Parties
1- filerCIK 0001789032
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 5:01 PM ET
- Size
- 11.0 KB